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BACKGROUND Patients with coronary artery disease who undergo
stent implantation and have concomitant indication for long term oral
anticoagulation represent a considerable percentage of the overall
population. To date there is still no consensus about the optimal
antithrombotic strategy to choose in this kind of patients, due to the
difﬁcult balance between an increased risk of bleeding and throm-
boembolic complications. Aim of this meta-analysis was to evaluate
risk and beneﬁts of triple antihrombotic therapy versus dual anti-
platelet therapy in patients undergoing coronary stent implantation,
requiring long term oral anticoagulation.
METHODS We performed formal searches of PubMed, EMBASE,
Cochrane central register of controlled trials and major international
scientiﬁc session abstracts from January 1990 to September 2014
regarding the use of triple antithrombotic therapy versus dual
antithrombotic therapy in patients undergoing percutaneous coronary
stent implantation that required chronic oral anticoagulation. Data
regarding study design, inclusion/exclusion criteria, number of pa-
tients, and selected endpoints was extracted by 2 investigators. Dis-
agreements were resolved by consensus.
RESULTS Twelve trials, with a total of 7838 patients undergoing stent
implantation with indication to long term oral anticoagulation were ﬁnally
included. A total of 2686 patients were treated with triple therapywhereas
5152 patients received dual antithrombotic therapy alone. The follow-up
period ranged from 270 to 2000 days. Mortality occurred in 10.8% of pa-
tients receiving triple therapy versus 16.7% of patients in dual therapy (OR
[95% CI] ¼ 0.80 [0.69-0.94], p ¼ 0.005; phet ¼ 0.0003). By meta-regres-
sion analysis no relationship was observed between reduction in mortality
and the risk of bleedings (p ¼ 0.10). Data regarding secondary endpoints
showed a signiﬁcant association between triple therapy and an increased
risk of bleedings (12.3% versus 9.9%) (OR [95% CI] ¼ 1.37 [1.16-1.62], p ¼
0.0002; phet ¼ 0.20), while we did not ﬁnd any signiﬁcant difference in
term of recurrence of myocardial infarction (p ¼ 0.39), stent thrombosis
(p ¼ 0.46) or stroke (p ¼ 0.15).
CONCLUSIONS This meta-analysis showed that among patients
undergoing coronary stent implantation, requiring chronic oral anti-
coagulation, the use of a triple antithrombotic therapy is associated with a
signiﬁcant reduction in mortality that largely outweighed the higher risk
of major bleeding complications associated with triple therapy.
CATEGORIES CORONARY: Pharmacology/Pharmacotherapy
KEYWORDS Anticoagulation, Antiplatelet therapy
TCT-78
Efﬁcacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54
Marc P. Bonaca,1 Deepak L. Bhatt,1 Philippe G. Steg,2 Andrej Budaj,3
Sameer Bansilal,4 Robert F. Storey,5 KyungAh Im,1 Giulia Magnani,1
T. Oude Ophuis,6 Michael Ruda,7 Christian Hamm,8 Jindrich Spinar,9
Robert Gabor Kiss,10 Rafael Diaz,11 Frans J. Van de Werf,12
Gilles Montalescot,13 Eva C. Jensen,14 Peter Held,14 Eugene Braunwald,1
Marc S. Sabatine1
1TIMI Study Group, Brigham and Women’s Hospital, Harvard Medical
School, Boston, MA; 2Hopital Bichat, Paris, France, Paris, France;
3Grochowski Hospital, Warsaw, Poland; 4Icahn School of Medicine at
Mount Sinai, New York, NY; 5University of Shefﬁeld, Shefﬁeld, UK;
6CWZ, Nijmegen, Netherlands; 7Russian Cardiology Research Center,
Moscow, Russian Federation; 8Kerckhoff Heart Center, Bad Nauheim,
Germany; 9Medical Faculty of Masaryk Univerity and University
Hospital Brno, Brno, Czech Republic; 10State Health Center, Budapest,
Hungary; 11Estudios Clínicos Latino América (ECLA), Rosario,
Argentina; 12University Hospitals Leuven, Leuven, Belgium; 13Hôpital
Pitié-Salpêtrière, Paris, France; 14AstraZeneca, Molndal, SwedenBACKGROUND Ticagrelor in patients with prior MI reduced the incidence
of CV death, MI, or stroke by 15-16% in PEGASUS-TIMI 54. We investigated
the efﬁcacy of ticagrelor in patients based on the presence and type of
stent.
METHODS Details of each patient’s most recent PCI were collected at
randomization. Stent thrombosis (ST) was prospectively adjudicated
according to ARC deﬁnitions with angiographic conﬁrmation when
available.
RESULTS In PEGASUS-TIMI 54, 4271 patients had no history of
stenting (20%), 8597 had a bare metal stent (BMS, 41%), and 8294 had
a drug-eluting stent (DES, 39%). The median time from PCI to
randomization was 1.7 yrs (IQR 1.2–2.3; 95% >1 year from PCI). Of the
patients with DES, 52% had received either everolimus or zotar-
olimus-eluting stents (EES or ZES), 27% had received sirolimus or
paclitaxel-eluting stents (SES or PES), and stent type was not speciﬁed
in the remainder. Among patients with stents randomized to placebo,
over a median of 33 months of follow-up, recurrent MI was most
frequent ischemic event (5.2%), followed by CV death (2.3%) and
stroke (1.7%), whereas ARC deﬁnite ST was rare (0.7%). Ticagrelor
consistently reduced CV death, MI, or stroke regardless of stenting or
stent type (pooled ticagrelor vs placebo; Fig Left) with similar
magnitude of beneﬁt for each dose and for each of the components.
Rates of deﬁnite ST were 0.38% with BMS, 1.01% with SES or PES,
and 0.65% with EES or ZES. Ticagrelor 90 mg bid signiﬁcantly
reduced ST whereas there was a trend with ticagrelor 60 mg bid
(Fig Right). The effect was even more pronounced for both doses
when patients were on study drug: HR 0.30 (0.14-0.65) & HR 0.66
(0.37-1.17), respectively.
CONCLUSIONS Patients with a history of MI more than 1 year from
PCI remain at heightened risk for ischemic events, predominantly MI,
CV death, and stroke, with stent thrombosis being rare. Long-term
ticagrelor reduces CVD/MI/Stroke regardless of stenting history and
reduces stent thrombosis in patients with stents.
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BACKGROUND In the CHAMPION PHOENIX trial, the potent, rapidly
acting, intravenous ADP antagonist cangrelor reduced the 48-hour
incidence of major adverse cardiac events (MACE; death, MI, stent
thrombosis, or repeat ischemia-driven revascularization) compared to
a loading dose of clopidogrel across a broad cross-section of patients
undergoing PCI. Whether this is true in patients with simple and
complex coronary anatomy is unknown.
